Unit of Endocrinology and Metabolism, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy ; Azienda USL, Modena, Italy.
Unit of Endocrinology and Metabolism, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy ; Center of Genomic Research, University of Modena and Reggio Emilia, Modena, Italy.
Eur Thyroid J. 2014 Jun;3(2):101-8. doi: 10.1159/000358590. Epub 2014 Jun 7.
Thyroidectomized patients need variable doses of levothyroxine (LT4) to obtain target thyroid-stimulating hormone (TSH) levels. Individual feedback set-points have been hypothesized and the influence of several genes in the regulation of the pituitary-thyroid axis has been demonstrated.
We hypothesized that genetic variants of the TRHR gene could be associated with a different hypothalamo-pituitary sensitivity to thyroid hormone feedback.
We retrospectively analyzed 84 thyroidectomized patients with no residual thyroid function and undetectable thyroglobulin levels. Patients were evaluated under LT4 resulting in TSH levels detectable but <0.5 μIU/ml. The two SNPs rs3134105 and rs3110040 were identified as informative markers of the TRHR gene. Genotyping was performed using high-resolution melting technology. Genotype distribution was compared between the patients and 99 euthyroid controls.
The selected SNPs were in linkage disequilibrium and only rs3134105 was further considered. A significant difference between the three possible genotypes for rs3134105 was found for TSH (p = 0.04) and free thyroxine (fT4)/TSH ratio (p = 0.02). Moreover, despite similar serum concentrations of free triiodothyronine (fT3) and fT4, carriers of at least one A allele of rs3134105 had significantly lower serum TSH levels (p = 0.01) as well as higher fT3/TSH (p = 0.01) and fT4/TSH ratios (p < 0.01).
We demonstrated an association between serum TSH levels and discrete alleles of the TRHR gene in totally thyroidectomized patients under LT4 therapy. Therefore, the TRHR gene seems to be a determinant of hypothalamo-pituitary sensitivity to LT4.
甲状腺切除术后的患者需要服用不同剂量的左旋甲状腺素(LT4)来达到目标促甲状腺激素(TSH)水平。已经假设了个体反馈设定点,并且已经证明了垂体-甲状腺轴的几个基因在调节中的作用。
我们假设 TRHR 基因的遗传变异可能与甲状腺激素反馈对下丘脑-垂体的敏感性不同有关。
我们回顾性分析了 84 例甲状腺功能完全切除且甲状腺球蛋白水平无法检测的患者。患者在 LT4 治疗下进行评估,结果导致 TSH 水平可检测但 <0.5 μIU/ml。rs3134105 和 rs3110040 这两个 SNP 被确定为 TRHR 基因的信息性标记物。使用高分辨率熔解技术进行基因分型。将患者与 99 例甲状腺功能正常的对照者的基因型分布进行比较。
所选 SNP 处于连锁不平衡状态,仅进一步考虑 rs3134105。rs3134105 的三个可能基因型之间的 TSH(p=0.04)和游离甲状腺素(fT4)/TSH 比值(p=0.02)存在显著差异。此外,尽管血清游离三碘甲状腺原氨酸(fT3)和 fT4 的浓度相似,但至少携带一个 rs3134105 的 A 等位基因的患者的血清 TSH 水平显著降低(p=0.01),同时 fT3/TSH(p=0.01)和 fT4/TSH 比值(p<0.01)也更高。
我们在 LT4 治疗下的完全甲状腺切除术后患者中证实了血清 TSH 水平与 TRHR 基因的离散等位基因之间存在关联。因此,TRHR 基因似乎是 LT4 对下丘脑-垂体敏感性的决定因素。